近日，微光基因宣布完成Pre-A轮融资，融资总额达到数千万元人民币。此次融资将助力微光基因快速推进针对未满足临床需求的常见病表观遗传编辑管线研究。 目前，微光基因聚力从生命源头探索疾病治愈方案，专注于多元化常见病的管线布局。杰出的研发团队，突破性的底层表观遗传编辑技术和成熟的递送打造出极具潜力的药界新星。 微光基因已实现从底层工具平台到下游药物开发全流程覆盖，不断优化微光基因编辑的分子利剑；依托清晰的自主IP布局全球市场，同时积极拓展对外合作，竭力为全球患者贡献微光基因“一针即愈”的基因治疗方案，打造“立足中国，走向全球”的体内基因表观遗传编辑品牌。微光基因表示，本次融资完成以后将加快速推进核心管线临床研究，同时布局多个全球first-in-class管线。 微光基因CEO胡洋博士表示：非常感谢新老股东对微光基因及团队的肯定和支持。微光基因以创新为驱动，布局全球领先的体内基因编辑技术，专注于通过RNP/mRNA-VLP/LNP递送系统开发新一代体内基因编辑药物，为患者提供更优治疗选择。 内容来源于网络，如有侵权，请联系删除。

Jan. 21, 2025 -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced today announced it has entered into agreements with certain holders of its existing warrants exercisable for 4,971,110 shares of its common stock, in the aggregate, to exercise outstanding warrants at a reduced exercise price of $0.751 per share, in exchange for new warr

January 15, 2025 -- Silexion Therapeutics Corp (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the pricing of a public offering of an aggregate of 3,703,703 of the Company’s ordinary shares (or ordinary share equivalents) and warrants to purchase up to 3,703,703 ordinary shares at a combined public offering price of $1.35 per share (or per ordinary share equivalent) and accom

Jan. 15, 2025 -- Hinge Bio, Inc., a privately-held biotechnology company, today announced the close of a Series A’ financing led by Point72. Joining Point72 are Ridgeback Capital, InVivium Capital, and Lightswitch Capital, among others. The proceeds will support entry of the Company’s lead product candidate, HB2198, into a Phase 1 clinical trial in patients living with Systemic Lupus Erythematosus (“Lupus”) as well as development of additional therapeutics from Hinge Bio’s proprietary GEM-DIMER

Highly experienced management team with a successful track record in advancing compounds from target identification to commercialization Top-tier global investors fund the company through clinical proof of concept of its lead program and IND-enablement of bispecifics Lead program is a phase 2-ready, long-acting anti-TSLP monoclonal antibody with potential to be first-to-market with dosing every 6 months Building a discovery pipeline of long-acting bispecifics harnessing validated targets and syn

CHF 50 Million extension round co-led by Cormorant Asset Management, with participation from other existing investors Proceeds will be used to support the advancement of multiple first-in-class and best-in-class programs into clinical development Jan. 09, 2025 -- Numab Therapeutics AG (“Numab”), a clinical stage biotechnology company advancing a proprietary pipeline of multi-specific antibodies in immunology and oncology, announced today the closing of an oversubscribed CHF 50 million (approx

Angelini Ventures co-leads alongside Invivo Partners with participation from Innovestor’s Life Science Fund and other existing investors Financing will support clinical development of Neumirna‘s lead asset NMT.001, a potential disease-modifying Antisense Oligonucleotide (ASO) therapy for drug-resistant epilepsy, as well as expand its R&D capabilities and scale its pioneering drug discovery platform Angelini Venture’s investment in Neumirna marks its 5th in the field of neurological disorders and

— HUTCHMED continues to deliver on its strategy outlined in November 2022 to create value, prioritize its portfolio and bring innovative medicines to patients globally — — Divestment proceeds to advance HUTCHMED’s pipeline and core innovative medicines business — — Focused R&D investment includes HUTCHMED’s proprietary antibody-targeted therapy conjugate platform, with first candidates expected to enter clinical trials in the second half of 2025 — Jan. 01, 2025 -- HUTCHMED (China) Limited (“HUT

Intend to announce updated clinical data from Phase 1/2 VBP301 trial of VCAR33ALLO in the first half of 2025 and updated clinical data from Phase 1/2a VBP101 trial of trem-cel in combination with Mylotarg in the second half of 2025 Extends cash runway through release of updated data from VBP101 and VBP301 trials in 2025 Dec. 27, 2024 -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it has entered into a securities purchase agreement for a priv

Dec. 31, 2024 -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced the closing of up to $12.4 million consisting of $2.4 million up front in the form of senior secured convertible notes at $3.00 per share, subject to adjustment, and an equity line of credit (the “ELOC”) for up to $10 million